TSHA vs. BBIO
TSHA (Taysha Gene Therapies, Inc.) and BBIO (BridgeBio Pharma, Inc.) are both stocks. Both operate in the Biotechnology industry within the Healthcare sector. Over the past 5 years, TSHA returned -23.63%/yr vs 3.04%/yr for BBIO. At a 0.30 correlation, their price movements are largely independent.
Performance
TSHA vs. BBIO - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, TSHA achieves a 18.73% return, which is significantly higher than BBIO's -9.90% return.
TSHA
- 1D
- 1.71%
- 1M
- 18.94%
- YTD
- 18.73%
- 6M
- 11.43%
- 1Y
- 165.45%
- 3Y*
- 114.68%
- 5Y*
- -23.63%
- 10Y*
- —
BBIO
- 1D
- 4.00%
- 1M
- -0.29%
- YTD
- -9.90%
- 6M
- -10.60%
- 1Y
- 65.16%
- 3Y*
- 63.88%
- 5Y*
- 3.04%
- 10Y*
- —
TSHA vs. BBIO - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
TSHA Taysha Gene Therapies, Inc. | 18.73% | 217.92% | -2.26% | -21.68% | -80.60% | -56.10% | 19.28% |
BBIO BridgeBio Pharma, Inc. | -9.90% | 178.75% | -32.03% | 429.79% | -54.32% | -76.54% | 83.98% |
Correlation
The correlation between TSHA and BBIO is 0.28, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.28 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.25 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.31 |
Correlation (All Time) Calculated using the full available price history since Sep 24, 2020 | 0.30 |
Fundamentals
TSHA:
$2.39B
BBIO:
$13.42B
TSHA:
-$0.39
BBIO:
-$3.76
TSHA:
292.29
BBIO:
23.53
TSHA:
$7.47M
BBIO:
$566.04M
TSHA:
$6.89M
BBIO:
$538.20M
TSHA:
-$130.51M
BBIO:
-$602.24M
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
TSHA vs. BBIO — Risk / Return Rank
TSHA
BBIO
TSHA vs. BBIO - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Taysha Gene Therapies, Inc. (TSHA) and BridgeBio Pharma, Inc. (BBIO). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| TSHA | BBIO | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.49 | ||
| Sortino ratioReturn per unit of downside risk | +1.06 | ||
| Omega ratioGain probability vs. loss probability | 1.36 | 1.28 | +0.08 |
| Calmar ratioReturn relative to maximum drawdown | 5.35 | 3.23 | +2.11 |
| Martin ratioReturn relative to average drawdown | 11.14 | 7.61 | +3.53 |
Loading charts...
Drawdowns
TSHA vs. BBIO - Drawdown Comparison
The maximum TSHA drawdown since its inception was -98.14%, which is greater than BBIO's maximum drawdown of -92.80%. Use the drawdown chart below to compare losses from any high point for TSHA and BBIO.
Loading charts...
Drawdown Indicators
| TSHA | BBIO | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.14% | -92.80% | -5.34% |
Max Drawdown (1Y)Largest decline over 1 year | -31.13% | -20.25% | -10.88% |
Max Drawdown (3Y)Largest decline over 3 years | -72.90% | -49.08% | -23.82% |
Max Drawdown (5Y)Largest decline over 5 years | -97.76% | -91.89% | -5.87% |
Current DrawdownCurrent decline from peak | -79.43% | -13.75% | -65.68% |
Average DrawdownAverage peak-to-trough decline | -76.85% | -45.68% | -31.17% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 14.91% | 8.59% | +6.32% |
Volatility
TSHA vs. BBIO - Volatility Comparison
Taysha Gene Therapies, Inc. (TSHA) has a higher volatility of 15.00% compared to BridgeBio Pharma, Inc. (BBIO) at 9.64%. This indicates that TSHA's price experiences larger fluctuations and is considered to be riskier than BBIO based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| TSHA | BBIO | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 15.00% | 9.64% | +5.36% |
Volatility (6M)Calculated over the trailing 6-month period | 49.27% | 34.37% | +14.90% |
Volatility (1Y)Calculated over the trailing 1-year period | 87.56% | 46.50% | +41.06% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 136.69% | 85.96% | +50.73% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 130.29% | 83.67% | +46.62% |
Dividends
TSHA vs. BBIO - Dividend Comparison
Neither TSHA nor BBIO has paid dividends to shareholders.
Financials
TSHA vs. BBIO - Financials Comparison
This section allows you to compare key financial metrics between Taysha Gene Therapies, Inc. and BridgeBio Pharma, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
TSHA and BBIO have a correlation of 0.28, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
TSHA has higher volatility (15.00%) compared to BBIO (9.64%). In terms of maximum drawdown, TSHA dropped -98.14% vs BBIO's -92.80%.
TSHA currently has the higher Sharpe Ratio (1.91 vs 1.41), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for TSHA and BBIO
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer